Insider Insights
02.03.2023
ABPI sets out new proposals in VPAG

ABPI announces new VPAG, which focuses on restoring the commercially competitive environment for lif...

Read more
Insider Insights
24.02.2023
The EU has a new project to find payment models fo...

Project to help the EU develop new pricing and payment models to fund high-priced drugs and relieve ...

Read more
Insider Insights
22.02.2023
NICE announces the development of a new rapid revi...

New process to assess clinical and cost-effectiveness of COVID-19 treatments to get these medicines ...

Read more
Insider Insights
17.02.2023
Spain’s Ministry of Health copies NICE, and ...

Spain will ask pharmaceutical companies to submit their economic evaluation studies to reviewed late...

Read more
Insider Insights
09.02.2023
New criteria for ATMPs which must follow quality r...

The Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...

Read more
Insider Insights
08.02.2023
First Adalimumab Biosimilar Launch in the USA

The first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...

Read more
Insider Insights
02.02.2023
NICE has recommended Yescarta as the first CAR T-c...

NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...

Read more
Insider Insights
01.02.2023
Price cuts for generics could exacerbate ongoing p...

The economic committee for health products (CEPs) have announced a price reduction of €67 that wil...

Read more
Insider Insights
25.01.2023
UK to introduce first-of-its-kind framework to aid...

MHRA announces UK will introduce new framework aimed at making the manufacture of innovative medicin...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.